VMS symptoms and cardiovascular implications
Rebecca Thurston, PhD, sits down to discuss her research presented at the NAMS Annual Meeting on vasomotor symptoms and cardiovascular health.
In an exclusive video interview, Rebecca Thurston, PhD, sits down with Contemporary OB/GYN® Managing Editor Morgan Petronelli to discuss her presentations from the North American Menopause Society's (NAMS) Annual Meeting held recently in Atlanta, Georgia, from October 12-15.
Thurston is the chair of the Pittsburgh Foundation; a professor of psychiatry, psychology, and epidemiology at the University of Pittsburgh where she directs the Women's Behavioral Health program; and is the NAMS 2022 Scientific program chair.
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 3rd 2021In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Listen
Lessons in asking patients' gender identity and sexual orientation
October 23rd 2023A recent study presented at the 2023 American Academy of Pediatrics National Conference & Exhibition evaluated how clinicians can ask patients' sexual orientation and gender identity for EHR documentation.
Read More
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
